Fulton Bank N.A. Buys New Position in Exact Sciences Co. (NASDAQ:EXAS)

Fulton Bank N.A. bought a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,384 shares of the medical research company’s stock, valued at approximately $367,000.

Other large investors have also bought and sold shares of the company. Personal CFO Solutions LLC acquired a new position in shares of Exact Sciences in the 4th quarter valued at $233,000. Regal Investment Advisors LLC boosted its position in shares of Exact Sciences by 13.6% in the 4th quarter. Regal Investment Advisors LLC now owns 8,310 shares of the medical research company’s stock valued at $615,000 after purchasing an additional 992 shares during the period. Frontier Capital Management Co. LLC boosted its position in shares of Exact Sciences by 24.1% in the 4th quarter. Frontier Capital Management Co. LLC now owns 582,221 shares of the medical research company’s stock valued at $43,073,000 after purchasing an additional 113,154 shares during the period. Altitude Crest Partners Inc. acquired a new position in shares of Exact Sciences in the 4th quarter valued at $7,334,000. Finally, Harbert Fund Advisors Inc. acquired a new position in shares of Exact Sciences in the 4th quarter valued at $507,000. Institutional investors own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In related news, EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.36% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Wells Fargo & Company assumed coverage on Exact Sciences in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price target for the company. Stifel Nicolaus reduced their price objective on Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Canaccord Genuity Group reissued a “buy” rating and issued a $75.00 price objective on shares of Exact Sciences in a research note on Friday, September 13th. Raymond James reissued a “market perform” rating on shares of Exact Sciences in a research note on Thursday, September 26th. Finally, Evercore ISI increased their price objective on Exact Sciences from $72.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $78.38.

Exact Sciences Stock Down 0.1 %

EXAS opened at $68.52 on Thursday. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The business has a 50-day moving average of $62.66 and a 200-day moving average of $56.54. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.17 and a quick ratio of 1.98. The company has a market capitalization of $12.64 billion, a PE ratio of -51.91 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business had revenue of $699.26 million for the quarter, compared to the consensus estimate of $690.02 million. During the same period last year, the business earned ($0.45) EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts forecast that Exact Sciences Co. will post -0.87 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.